Embattled pain drug developer QrXPharma has sent mixed messages to the market, urging shareholders to vote against a spill of two directors proposed by disgruntled investor Lang Walker, while also flagging it was considering giving up on its technology.
The company has set a general meeting date of July 7, giving the property development mogul a month to convince shareholders to support the axing of QrXPharma chairman and ResMed founder Peter Farrell and the company’s founder Gary Pace.
Loading...
Jessica Gardner is Deputy editor - News. She has previously edited the Companies and Markets section. Connect with Jessica on Twitter. Email Jessica at jgardner@afr.com
